The heart in liver transplantation

Journal of Hepatology

Volumn 54, Issue 4, 2011, Pages 810-822

  Ripoll, Cristina ^a   Yotti, Raquel ^a   Bermejo, Javier ^a   Bañares, Rafael ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Cirrhotic cardiomyopathy; Coronary artery disease; Heart function; Liver cirrhosis; Liver transplantation; Portopulmonary hypertension

Indexed keywords

ANGIOCARDIOGRAPHY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CIRROHOTIC CARDIOMYOPATHY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ECHOGRAPHY; ELECTROCARDIOGRAPHY; END STAGE LIVER DISEASE; EXERCISE TEST; FAMILIAL AMYLOID POLYNEUROPATHY; HEART CATHETERIZATION; HEART DISEASE; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HUMAN; INTRAOPERATIVE PERIOD; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTOPULMONARY HYPERTENSION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW;

EID: 79952708902     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.11.003     Document Type: Note

References (161)

1. Kotin P, Hall EM. "Cardiac" or congestive cirrhosis of liver. Am J Pathol 1951;27:561-571.
2. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953;32:1025-1033.
3. Kowalski HJ, Abelmann WH, Mc NW. The cardiac output in patients with cirrhosis of the liver and tense ascites with observations on the effect of paracentesis. J Clin Invest 1954;33:768-773.
4. Arranz J, Soriano A, Garcia I, Concepcion MT, Navarro J, Arteaga A, et al. Effect of proinflammatory cytokines (IL-6, TNF-alpha, IL-1beta) on hemodynamic performance during orthotopic liver transplantation. Transplant Proc 2003;35:1884-1887. (Pubitemid 37093750)
5. Aggarwal S, Kang Y, Freeman JA, Fortunato Jr FL, Pinsky MR. Postreperfusion syndrome: hypotension after reperfusion of the transplanted liver. J Crit Care 1993;8:154-160. (Pubitemid 23275998)
6. Ripoll C, Catalina MV, Yotti R, Olmedilla L, Perez-Pena J, Lo Iacono O, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 2008;85:1766-1772.
7. Brigden W, Robinson J. Alcoholic heart disease. Br Med J 1964;2:1283-1289.
8. Mathews Jr EC, Gardin JM, Henry WL, Del Negro AA, Fletcher RD, Snow JA, et al. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure. Am J Cardiol 1981;47:570-578. (Pubitemid 11137653)
9. Lazarevic AM, Nakatani S, Neskovic AN, Marinkovic J, Yasumura Y, Stojicic D, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000;35:1599-1606. (Pubitemid 30307506)
10. La Vecchia LL, Bedogni F, Bozzola L, Bevilacqua P, Ometto R, Vincenzi M. Prediction of recovery after abstinence in alcoholic cardiomyopathy: role of hemodynamic and morphometric parameters. Clin Cardiol 1996;19:45-50. (Pubitemid 26314350)
11. Guillo P, Mansourati J, Maheu B, Etienne Y, Provost K, Simon O, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997;79:1276-1278. (Pubitemid 27255182)
12. Corrao G, Rubbiati L, Bagnardi V, Zambon A, Poikolainen K. Alcohol and coronary heart disease: a meta-analysis. Addiction 2000;95:1505-1523.
13. Britton KA, Gaziano JM, Sesso HD, Djousse L. Relation of alcohol consumption and coronary heart disease in hypertensive male physicians (from the Physicians' Health Study). Am J Cardiol 2009;104:932-935.
14. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
15. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Nguyen TT, Botello G, et al. Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis. Am J Cardiol 2006;98:954-959. (Pubitemid 44402270)
16. Ptaszek LM, Price ET, Hu MY, Yang PC. Early diagnosis of hemochromatosis-related cardiomyopathy with magnetic resonance imaging. J Cardiovasc Magn Reson 2005;7:689-692. (Pubitemid 41176836)
17. Candell-Riera J, Lu L, Seres L, Gonzalez JB, Batlle J, Permanyer-Miralda G, et al. Cardiac hemochromatosis: beneficial effects of iron removal therapy. An echocardiographic study. Am J Cardiol 1983;52:824-829. (Pubitemid 13023768)
18. Cecchetti G, Binda A, Piperno A, Nador F, Fargion S, Fiorelli G. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. Eur Heart J 1991;12:224-230.
19. Brandhagen DJ. Liver transplantation for hereditary hemochromatosis. Liver Transplant 2001;7:663-672. (Pubitemid 32771464)
20. Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005;129:494-503. (Pubitemid 41096637)
21. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with nonalcoholic fatty liver disease. Diabet Med 2006;23:403-409.
22. Arslan U, Turkoglu S, Balcioglu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007;18:433-436. (Pubitemid 47262963)
23. Choi SY, Kim D, Kim HJ, Kang JH, Chung SJ, Park MJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 2009;104:1953-1960.
24. Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 2009;40:571-575.
25. McKimmie RL, Daniel KR, Carr JJ, Bowden DW, Freedman BI, Register TC, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study. Am J Gastroenterol 2008;103:3029-3035.
26. Delahaye N, Rouzet F, Sarda L, Tamas C, Dinanian S, Plante-Bordeneuve V, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore) 2006;85:229-238. (Pubitemid 44107181)
27. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157.
28. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;32:141-156.
29. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010;53:179-190.
30. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 2001;101:621-628.
31. Pimenta J, Paulo C, Gomes A, Silva S, Rocha-Goncalves F, Bettencourt P. B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 2010;30:1059-1066.
32. Quinones MA, Gaasch WH, Alexander JK. Influence of acute changes in preload, afterload, contractile state and heart rate on ejection and isovolumic indices of myocardial contractility in man. Circulation 1976;53:293-302.
33. Triulzi MO, Castini D, Ornaghi M, Vitolo E. Effects of preload reduction on mitral flow velocity pattern in normal subjects. Am J Cardiol 1990;66:995-1001. (Pubitemid 20360595)
34. Eimer MJ, Wright JM, Wang EC, Kulik L, Blei A, Flamm S, et al. Frequency and significance of acute heart failure following liver transplantation. Am J Cardiol 2008;101:242-244.
35. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007;56:869-875. (Pubitemid 46854206)
36. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-1218. (Pubitemid 37314829)
37. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-447. (Pubitemid 41061097)
38. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105-110.
39. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318. (Pubitemid 47300435)
40. Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57:268-278. (Pubitemid 351158057)
41. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34. (Pubitemid 28041530)
42. Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003;23:243-248. (Pubitemid 37265799)
43. Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Moller S. Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J Hepatol 2005;43:637-644.
44. Genovesi S, Prata Pizzala DM, Pozzi M, Ratti L, Milanese M, Pieruzzi F, et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond) 2009;116:851-859.
45. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet 1993;341:1423-1428. (Pubitemid 23161442)
46. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996;23:1128-1134. (Pubitemid 26137057)
47. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022. (Pubitemid 38269278)
48. Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008;48:415-421.
49. Henriksen JH, Bendtsen F, Hansen EF, Moller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004;40:239-246. (Pubitemid 38115828)
50. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transplant 2002;8:690-700.
51. Pozzi M, Grassi G, Ratti L, Favini G, Dell'Oro R, Redaelli E, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005;100:1110-1116. (Pubitemid 40769049)
52. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.
53. Pilatis ND, Jacobs LE, Rerkpattanapipat P, Kotler MN, Owen A, Manzarbeitia C, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transplant 2000;6:85-91. (Pubitemid 30123373)
54. Torregrosa M, Genesca J, Gonzalez A, Evangelista A, Mora A, Margarit C, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation 2001;71:572-574. (Pubitemid 32207211)
55. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003;37:401-409. (Pubitemid 36152540)
56. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006;44:1502-1510. (Pubitemid 44953655)
57. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transplant 2000;6:443-450. (Pubitemid 30489117)
58. Murray KF, Carithers Jr RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-1432. (Pubitemid 40770295)
59. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O'Mahony C, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant 2006;6:2177-2182. (Pubitemid 44199553)
60. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007;7:1258-1264. (Pubitemid 46643089)
61. Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transplant 2007;13:875-885. (Pubitemid 46939441)
62. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transplant 2008;14:287-291. (Pubitemid 351425480)
63. Gough MS, White RJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transplant 2009;15:30-36.
64. Hemnes AR, Robbins IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transplant 2009;15:15-19.
65. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension. Chest 2010, in press.
66. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006;130:120-126. (Pubitemid 43049842)
67. Keeffe BG, Valantine H, Keeffe EB. Detection and treatment of coronary artery disease in liver transplant candidates. Liver Transplant 2001;7:755-761. (Pubitemid 32851294)
68. Carey WD, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 1995;59:859-864.
69. Plotkin JS, Benitez RM, Kuo PC, Njoku MJ, Ridge LA, Lim JW, et al. Dobutamine stress echocardiography for preoperative cardiac risk strati- fication in patients undergoing orthotopic liver transplantation. Liver Transplant Surg 1998;4:253-257. (Pubitemid 28323742)
70. Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol 2006;98:178-181. (Pubitemid 43975507)
71. Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002;74:1007-1012. (Pubitemid 35191252)
72. Fili D, Vizzini G, Biondo D, Pietrosi G, Volpes R, Palazzo U, et al. Clinical burden of screening asymptomatic patients for coronary artery disease prior to liver transplantation. Am J Transplant 2009;9:1151-1157.
73. Smith Jr SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, et al. Preventing heart attack and death in patients with coronary disease. Circulation 1995;92:2-4.
74. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, Jacobs AK, Kern MJ, King 3rd SB, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-175.
75. Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009;136:1651-1658.
76. Klemperer JD, Ko W, Krieger KH, Connolly M, Rosengart TK, Altorki NK, et al. Cardiac operations in patients with cirrhosis. Ann Thorac Surg 1998;65:85-87. (Pubitemid 28105875)
77. Bizouarn P, Ausseur A, Desseigne P, Le Teurnier Y, Nougarede B, Train M, et al. Early and late outcome after elective cardiac surgery in patients with cirrhosis. Ann Thorac Surg 1999;67:1334-1338. (Pubitemid 29320228)
78. Csikesz NG, Nguyen LN, Tseng JF, Shah SA. Nationwide volume and mortality after elective surgery in cirrhotic patients. J Am Coll Surg 2009;208:96-103.
79. Shaheen AA, Kaplan GG, Hubbard JN, Myers RP. Morbidity and mortality following coronary artery bypass graft surgery in patients with cirrhosis: a population-based study. Liver Int 2009;29:1141-1151.
80. Filsoufi F, Salzberg SP, Rahmanian PB, Schiano TD, Elsiesy H, Squire A, et al. Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transplant 2007;13:990-995. (Pubitemid 47163191)
81. Benedetti E, Massad MG, Chami Y, Wiley T, Layden TJ. Is the presence of surgically treatable coronary artery disease a contraindication to liver transplantation? Clin Transplant 1999;13:59-61.
82. Alba AC, Verocai Flaman F, Granton J, Delgado DH. Patent foramen ovale does not have a negative impact on early outcomes in patients undergoing liver transplantation. Clin Transplant 2010, in press.
83. Alper I, Ulukaya S, Demir F, Kilic M. Effects of cardiac valve dysfunction on perioperative management of liver transplantation. Transplant Proc 2009;41:1722-1726.
84. Parker BM, Mayes JT, Henderson JM, Savage RM. Combined aortic valve replacement and orthotopic liver transplantation. J Cardiothorac Vasc Anesth 2001;15:474-476. (Pubitemid 32756210)
85. Eckhoff DE, Frenette L, Sellers MT, McGuire BM, Contreras JL, Bynon JS, et al. Combined cardiac surgery and liver transplantation. Liver Transplant 2001;7:60-61. (Pubitemid 32060917)
86. Volk ML, Hernandez JC, Lok AS, Marrero JA. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transplant 2007;13:1515-1520. (Pubitemid 350168191)
87. Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant 1995;9:463-471.
88. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998;97:1876-1887. (Pubitemid 28213637)
89. Thuluvath PJ. When is diabetes mellitus a relative or absolute contraindication to liver transplantation? Liver Transplant 2005:S25-29.
90. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002;36:513-520. (Pubitemid 34407340)
91. Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984;54:852-855. (Pubitemid 14006160)
92. Keller H, Bezjak V, Stegaru B, Buss J, Holm E, Heene DL. Ventricular function in cirrhosis and portasystemic shunt: a two-dimensional echocardiographic study. Hepatology 1988;8:658-662.
93. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996;31:279-284.
94. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999;97:259-267. (Pubitemid 29425319)
95. Piscaglia F, Valgimigli M, Rapezzi C, Ferlito M, Gaiani S, Siringo S, et al. Left ventricular volumes in liver cirrhosis. Dig Liver Dis 2000;32:392-397. (Pubitemid 30612335)
96. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transplant 2000;6:453-458. (Pubitemid 30489119)
97. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24:861-880. (Pubitemid 39504442)
98. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010;55:1600-1607.
99. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-193. (Pubitemid 40139730)
100. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-1453.
101. McAvoy NC, Kochar N, McKillop G, Newby DE, Hayes PC. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transplant 2008;14:1725-1731.
102. Folsom AR, Kronmal RA, Detrano RC, O'Leary DH, Bild DE, Bluemke DA, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence. the Multi- Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008;168:1333-1339. (Pubitemid 351930841)
103. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996;61:1180-1188. (Pubitemid 26134767)
104. Kryzhanovski VA, Beller GA. Usefulness of preoperative noninvasive radionuclide testing for detecting coronary artery disease in candidates for liver transplantation. Am J Cardiol 1997;79:986-988. (Pubitemid 27197942)
105. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation 2000;69:2354-2356. (Pubitemid 30409002)
106. Harinstein ME, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant 2008;8:1523-1528. (Pubitemid 351989500)
107. Umphrey LG, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG, et al. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. Liver Transplant 2008;14:886-892. (Pubitemid 351895519)
108. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006;44:994-1002.
109. Tsutsui JM, Mukherjee S, Elhendy A, Xie F, Lyden ER, O'Leary E, et al. Value of dobutamine stress myocardial contrast perfusion echocardiography in patients with advanced liver disease. Liver Transplant 2006;12:592-599.
110. Davidson CJ, Gheorghiade M, Flaherty JD, Elliot MD, Reddy SP, Wang NC, et al. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol 2002;89:359-360. (Pubitemid 34113805)
111. Senzolo M, Bassanello M, Graziotto A, Zucchetta P, Cillo U, Maraglino G, et al. Microvascular autonomic dysfunction may justify false-positive stress myocardial perfusion imaging in patients with liver cirrhosis undergoing liver transplantation. Transplant Proc 2008;40:1916-1917.
112. Aydinalp A, Bal U, Atar I, Ertan C, Aktas A, Yildirir A, et al. Value of stress myocardial perfusion scanning in diagnosis of severe coronary artery disease in liver transplantation candidates. Transplant Proc 2009;41:3757-3760.
113. Melgosa MT, Ricci GL, Garcia-Pagan JC, Blanco I, Escribano P, Abraldes JG, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transplant 2010;16:348-356.
114. Ricci GL, Melgosa MT, Burgos F, Valera JL, Pizarro S, Roca J, et al. Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension. Liver Transplant 2007;13:1506-1514. (Pubitemid 350168190)
115. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648. (Pubitemid 29409407)
116. Findlay JY, Harrison BA, Plevak DJ, Krowka MJ. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transplant Surg 1999;5:381-387. (Pubitemid 29437015)
117. Sharma M, Yong C, Majure D, Zellner C, Roberts JP, Bass NM, et al. Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation. Am J Cardiol 2009;103:742-746.
118. Terziyski K, Andonov V, Marinov B, Kostianev S. Exercise performance and ventilatory efficiency in patients with mild and moderate liver cirrhosis. Clin Exp Pharmacol Physiol 2008;35:135-140.
119. Epstein SK, Ciubotaru RL, Zilberberg MD, Kaplan LM, Jacoby C, Freeman R, et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig Dis Sci 1998;43:1701-1707.
120. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001;49:268-275. (Pubitemid 32675122)
121. Epstein SK, Freeman RB, Khayat A, Unterborn JN, Pratt DS, Kaplan MM. Aerobic capacity is associated with 100-day outcome after hepatic transplantation. Liver Transplant 2004;10:418-424.
122. Chemla D, Jayais P, Ecoffey C, Declere AD, Lecarpentier Y. In vitro negative inotropic effect of plasma collected at the time of reperfusion in humans undergoing liver transplantation. Anesthesiology 1997;87:378-386.
123. Reich DL, Wood Jr RK, Emre S, Bodian CA, Hossain S, Krol M, et al. Association of intraoperative hypotension and pulmonary hypertension with adverse outcomes after orthotopic liver transplantation. J Cardiothorac Vasc Anesth 2003;17:699-702. (Pubitemid 38044896)
124. de la Morena G, Acosta F, Villegas M, Bento M, Sansano T, Bueno FS, et al. Ventricular function during liver reperfusion in hepatic transplantation. A transesophageal echocardiographic study. Transplantation 1994;58:306-310.
125. Krenn CG, Hoda R, Nikolic A, Greher M, Plochl W, Chevtchik OO, et al. Assessment of ventricular contractile function during orthotopic liver transplantation. Transplant Int 2004;17:101-104. (Pubitemid 38315873)
126. Safadi A, Homsi M, Maskoun W, Lane KA, Singh I, Sawada SG, et al. Perioperative risk predictors of cardiac outcomes in patients undergoing liver transplantation surgery. Circulation 2009;120:1189-1194.
127. Schnell F, Donal E, Lorho R, Lavoue S, Gacouin A, Compagnon P, et al. Severe left-sided heart failure early after liver transplantation. Liver Transplant 2009;15:1296-1305.
128. Hornsten R, Suhr OB, Jensen SM, Wiklund U. Outcome of heart rate variability and ventricular late potentials after liver transplantation for familial amyloidotic polyneuropathy. Amyloid 2008;15:187-195.
129. Wiklund U, Hornsten R, Olofsson BO, Suhr OB. Cardiac autonomic function does not improve after liver transplantation for familial amyloidotic polyneuropathy. Auton Neurosci 2010;156:124-130.
130. Glauser FL. Systemic hemodynamic and cardiac function changes in patients undergoing orthotopic liver transplantation. Chest 1990;98:1210-1215. (Pubitemid 20381290)
131. Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 1993;17:355-360. (Pubitemid 23072807)
132. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68-74. (Pubitemid 40038902)
133. Liu H, Lee SS. What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology 2005;42:1203-1205.
134. Fukazawa K, Gologorsky E, Manmohansingh V, Nishida S, Vigoda MM, Pretto Jr EA. Is the immediate reversal of diastolic dysfunction of cirrhotic cardiomyopathy after liver transplantation a sign of the metabolic etiology? Liver Transplant 2009;15:1417-1419.
135. Saner FH, Nadalin S, Pavlakovic G, Gu Y, Olde Damink SW, Gensicke J, et al. Portopulmonary hypertension in the early phase following liver transplantation. Transplantation 2006;82:887-891. (Pubitemid 44564033)
136. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transplant Surg 1996;2:426-430. (Pubitemid 26386861)
137. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transplant 2009;15:1662-1670.
138. Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transplant 2007;13:1109-1114. (Pubitemid 47305029)
139. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002;73:901-906. (Pubitemid 34252352)
140. Farrell FJ, Nguyen M, Woodley S, Imperial JC, Garcia-Kennedy R, Man K, et al. Outcome of liver transplantation in patients with hemochromatosis. Hepatology 1994;20:404-410. (Pubitemid 24233368)
141. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131-1137. (Pubitemid 27509293)
142. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999;44:743-748. (Pubitemid 29195928)
143. Valeriano V, Funaro S, Lionetti R, Riggio O, Pulcinelli G, Fiore P, et al. Modification of cardiac function in cirrhotic patients with and without ascites. Am J Gastroenterol 2000;95:3200-3205.
144. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995;22:326-332.
145. Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, et al. Humoral and cardiac effects of TIPS in cirrhotic patients with different "effective" blood volume. Hepatology 2003;38:1370-1377.
146. Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974;49:754-760.
147. Gould L, Shariff M, Zahir M, Di Lieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969;48:860-868.
148. Kelbaek H, Rabol A, Brynjolf I, Eriksen J, Bonnevie O, Godtfredsen J, et al. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. Clin Physiol 1987;7:35-41. (Pubitemid 17004440)
149. Carey EJ, Douglas DD. Effects of orthotopic liver transplantation on the corrected QT interval in patients with end-stage liver disease. Dig Dis Sci 2005;50:320-323. (Pubitemid 40311540)
150. Adigun AQ, Pinto AG, Flockhart DA, Gorski JC, Li L, Hall SD, et al. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol 2005;95:691-694. (Pubitemid 40255274)
151. Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003;38:461-467. (Pubitemid 36399249)
152. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 1991;12:207-216.
153. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-1517. (Pubitemid 37176734)
154. Puthumana L, Chaudhry V, Thuluvath PJ. Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. J Hepatol 2001;35:733-738. (Pubitemid 34717664)
155. Hansen S, Moller S, Bendtsen F, Jensen G, Henriksen JH. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J Hepatol 2007;47:373-380. (Pubitemid 47189606)
156. Vachiery F, Moreau R, Gadano A, Yang S, Sogni P, Hadengue A, et al. Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker. Dig Dis Sci 1996;41:1722-1726. (Pubitemid 26319745)
157. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009;104:2458-2466.
158. De BK, Majumdar D, Das D, Biswas PK, Mandal SK, Ray S, et al. Cardiac dysfunction in portal hypertension among patients with cirrhosis and noncirrhotic portal fibrosis. J Hepatol 2003;39:315-319.
159. Laffi G, Barletta G, La Villa G, Del Bene R, Riccardi D, Ticali P, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997;113:891-898. (Pubitemid 27381149)
160. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol 2002;97:142-148. (Pubitemid 34059778)
161. Kovacs A, Schepke M, Heller J, Schild HH, Flacke S. Short-term effects of transjugular intrahepatic shunt on cardiac function assessed by cardiac MRI: preliminary results. Cardiovasc Intervent Radiol 2010;33:290-296.